MedPath

Tagged News

Apollo Hospitals and Siemens Healthineers Launch AI-Driven Research Collaboration for Liver Disease Diagnostics in India

AI
  • Apollo Hospitals and Siemens Healthineers have established a research collaboration to develop AI-enabled diagnostic and imaging solutions for liver disease management, focusing on quantitative ultrasound imaging and clinical decision support tools.
  • The partnership specifically targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects 9-32% of India's population and poses significant diagnostic challenges due to its underestimated prevalence.
  • The collaboration aims to enhance early detection of liver fibrosis through AI-driven disease progression models, enabling timely interventions and cost-effective screening for improved patient outcomes.
  • A Master Research Agreement was formalized in March 2025, with an addendum signed in July 2025 establishing the framework for collaborative research on diagnostic and interventional ultrasound imaging for liver care.

SurgiVance Secures $2.2M NIH Grant to Advance Direct-to-Digital Pathology Platform

AIPrecision Medicine
  • SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology.
  • The platform enables direct-to-digital, in-office pathology using advanced imaging hardware and AI processing on whole tissue without traditional glass microscope slides.
  • Clinical studies will be conducted at NYU Langone Health, The Rockefeller University, Northwell Health, and Oregon Health & Science University targeting cancer at cellular and molecular levels.
  • The technology promises to deliver histopathologic diagnosis in minutes, potentially transforming cancer management and precision medicine through 3D molecular imaging biomarkers.

Answer ALS Launches AI-Powered Drug Discovery Initiative to Accelerate ALS Treatment Development

AIDrug Discovery
  • Answer ALS has launched LADDIA, a groundbreaking AI-powered drug discovery collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane University to accelerate ALS treatment development.
  • The initiative leverages the world's largest open-access ALS dataset through the Neuromine Data Portal and GATC Health's proprietary AI platform to identify druggable therapeutic targets.
  • Currently, there are no known viable treatments for ALS, making this AI-driven approach critical for identifying new therapeutic pathways for the neurodegenerative disease.
  • The collaboration will roll out in two phases, focusing first on building infrastructure and then activating collaborative projects to generate high-impact scientific outputs.

Nestmedic Partners with Curavit for U.S. Clinical Trial of AI-Enabled Prenatal Monitoring Device

AIFDA Approval
  • Nestmedic S.A. has selected Curavit Clinical Research to lead the U.S. clinical trial of PregnaOne, an AI-enabled remote prenatal monitoring solution designed to provide continuous insight into fetal and maternal well-being.
  • The FDA-required Non-Significant Risk study will enroll 50 expectant mothers across multiple U.S. sites over 11 months to evaluate the safety and effectiveness of home-based prenatal monitoring.
  • The trial aims to generate foundational evidence to support future regulatory approval in the U.S., with Curavit managing all aspects including IRB submissions, site selection, data management, and clinical study reporting.

Lantern Pharma Secures European Patent for AI-Developed Cancer Therapy LP-284

AIOncology
  • Lantern Pharma received European Patent Office allowance for LP-284, a next-generation acylfulvene targeting relapsed or refractory non-Hodgkin's lymphoma with patent exclusivity through early 2039.
  • The AI-developed drug candidate achieved clinical trial readiness in under three years at approximately $1.5-2.0 million cost and is currently in Phase 1 trials for aggressive NHL subtypes.
  • LP-284 has earned FDA Orphan Drug Designations for mantle cell lymphoma and high-grade B-cell lymphomas, addressing a $4 billion annual global blood cancer market.
  • The European patent strengthens Lantern's global intellectual property portfolio alongside existing patents in the US, Japan, India, and Mexico, positioning LP-284 for worldwide commercialization.

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503RecruitingPhase 1
Lantern Pharma Inc.
Posted 1/3/2023

MVP Health Care Partners with Renalytix to Expand Access to AI-Powered Kidney Disease Testing

AIPrecision MedicineFDA Approval
  • MVP Health Care and Renalytix announced a partnership to expand access to the FDA-approved kidneyintelX.dkd test for patients with type 2 diabetes and chronic kidney disease.
  • The collaboration aims to identify patients at higher risk for progressive kidney function decline earlier, enabling more targeted therapeutic interventions and personalized care plans.
  • The test will be available to all MVP customers in New York, including Medicare and Medicaid beneficiaries, and is recommended by KDIGO clinical guidelines.
  • Renalytix reports measurable improvements in patient outcomes and quality metrics, including HEDIS measures for blood pressure and HbA1c control in high-risk populations where the test is implemented.

Fangzhou and Novo Nordisk Partner to Create AI-Powered Chronic Disease Management Ecosystem in China

AI
  • Fangzhou Inc., China's leading online chronic disease management platform serving 49.2 million registered users, has signed a Memorandum of Understanding with Novo Nordisk to collaborate on managing diabetes and obesity through AI-powered solutions.
  • The partnership will leverage Novo Nordisk's expertise in diabetes and obesity treatment combined with Fangzhou's smart healthcare ecosystem to create comprehensive health management services including medication guidance, efficacy tracking, and health education.
  • The collaboration aims to shift from a "disease-centered" to a "health-centered" model, providing patients with more convenient one-stop healthcare services while supporting China's "Healthy China 2030" strategic objectives.
  • Both companies plan to explore further innovative collaborations in the medical industry's digital transformation to benefit patients with serious chronic diseases through early screening, diagnosis, and treatment implementation.

One Biosciences Secures €15 Million Series A to Advance AI-Powered Single-Cell Cancer Diagnostics Platform

AI
  • One Biosciences raised €15 million in Series A financing led by Redmile Group and Blast to advance its OneMap platform for single-cell cancer diagnostics.
  • The AI-powered platform generates detailed functional profiles of patient tumors to guide treatment decisions and improve patient selection for clinical trials.
  • Funding will accelerate clinical development of OneMap and support strategic partnerships with pharmaceutical and biotech companies.
  • The company's total funding now exceeds €20 million, positioning OneMap as a clinical tool for precision oncology applications.

Fifty1 Labs Partners with BioSpark AI to Accelerate Drug Repurposing Through Advanced Literature Mining

AI
  • Fifty1 AI Labs announces strategic partnership with intent to acquire BioSpark AI Technologies, combining AI-powered literature mining with predictive modeling for drug repurposing applications.
  • The collaboration has successfully structured over 2,000 real-world treatment pathways from medical literature using BioSpark's patented AI system for clinical data extraction.
  • The partnership aims to transform functional medicine by automating the analysis of patient journeys and treatment outcomes from vast volumes of unstructured clinical data.
  • Next phase involves AI-guided hypothesis generation using proprietary models to identify dose-response trends and synergistic drug combinations for clinical validation.

Velocity Clinical Research Partners with Palantir to Automate Clinical Trial Payment Reconciliation Using AI

AI
  • Velocity Clinical Research has announced a strategic partnership with Palantir Technologies to automate the complex payments reconciliation process in clinical trials using advanced artificial intelligence.
  • The collaboration integrates Palantir's agentic AI technology with Velocity's proprietary workflows, successfully processing and reconciling customer payment report entries while saving significant time for finance teams.
  • The automated reconciliation solution transforms months of manual effort into near-instantaneous insights, allowing finance teams to focus on strategic, high-value work instead of administrative tasks.
  • This partnership represents a significant step toward modernizing clinical trial operations and unlocking efficiencies that will benefit sponsors, sites, and patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.